Value of non-invasive fibrosis markers in chronic hepatitis D von Kalkan, C, Karakaya, F, Keskin, O, Kartal, A, Karatayli, E, Bozdayi, M, İdilman, R, Yurdcu, E, Yurdaydin, C

Volltext

A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study von Yurdaydin, C, Idilman, R, Keskin, O, Kalkan, C, Karakaya, M.F, Caliskan, A, Yurdcu, E, Karatayli, S.C, Bozdayi, M, Koh, C, Heller, T, Glenn, J

Volltext

The prenylation inhibitor lonafarnib can induce post-treatment viral clearance in patients with chronic delta hepatitis resulting in alt normalization and regression of fibrosis von Yurdaydin, C, Idilman, R, Kalkan, C, Karakaya, M.F, Caliskan, A, Keskin, O, Yurdcu, E, Karatayli, S.C, Bozdayi, M, Koh, C, Heller, T, Glenn, J

Volltext

FRI-142 - Value of non-invasive fibrosis markers in chronic hepatitis D von Kalkan, C., Karakaya, F., Keskin, O., Kartal, A., Karatayli, E., Bozdayi, M., İdilman, R., Yurdcu, E., Yurdaydin, C.

Volltext

GS-008 - A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study von Yurdaydin, C., Idilman, R., Keskin, O., Kalkan, C., Karakaya, M.F., Caliskan, A., Yurdcu, E., Karatayli, S.C., Bozdayi, M., Koh, C., Heller, T., Glenn, J.

Volltext

THU-161 - The prenylation inhibitor lonafarnib can induce post-treatment viral clearance in patients with chronic delta hepatitis resulting in alt normalization and regression of f... von Yurdaydin, C., Idilman, R., Kalkan, C., Karakaya, M.F., Caliskan, A., Keskin, O., Yurdcu, E., Karatayli, S.C., Bozdayi, M., Koh, C., Heller, T., Glenn, J.

Volltext